Joe C Mathew

Stories by Joe C Mathew

Dabur Pharma eyes US, Europe

Dabur Pharma eyes US, Europe

Rediff.com   8 Jan 2007

Dabur Pharma, a leading player in the domestic oncology segment, is busy finalising its marketing strategies for EU, the US and Australia.

Pharma policy to seek R&D watchdog

Pharma policy to seek R&D watchdog

Rediff.com   4 Jan 2007

The new pharma policy proposed by Chemicals Minister Ram Vilas Paswan is likely to call for a central mechanism to oversee research and development projects in the country.

Govt seeks more control on drug pricing

Govt seeks more control on drug pricing

Rediff.com   2 Jan 2007

It aims at slashing the average market prices from 10 to 30 per cent for low-end brands and from 30 to 60 per cent for high-end ones.

MNCs fail to launch patented drugs in India

MNCs fail to launch patented drugs in India

Rediff.com   2 Jan 2007

Apart from Roche's hepatitis medicine Pegasys, which received a patent in March 2005, there have been no major announcements on grant of product patents.

Pharma Link plans more tie-ups for drug marketing

Pharma Link plans more tie-ups for drug marketing

Rediff.com   29 Dec 2006

Pharma Link, a joint venture of leading pharmaceutical support service provider Interpharma Asia-Pacific

MNC pharma firms eyeing  duty relief

MNC pharma firms eyeing duty relief

Rediff.com   28 Dec 2006

Eli Lily, Sanofi Aventis, Bristol Myers approach chemicals ministry.

Govt gets cold feet on OTC drugs policy

Govt gets cold feet on OTC drugs policy

Rediff.com   23 Dec 2006

Pharma companies' hope to have several of their house hold remedy brands like Crocin made available through grocery shops across the country may not materialise.

Chemists to kick off retail plan in Kerala, Mahara

Chemists to kick off retail plan in Kerala, Mahara

Rediff.com   22 Dec 2006

All India Organisation of Chemists and Druggists, the apex body of over 500,000 chemists that manage the bulk of the Rs 50,000 crore

Domestic pharma firms take lead in R&D tie-up

Domestic pharma firms take lead in R&D tie-up

Rediff.com   20 Dec 2006

The domestic pharmaceuticals industry has proven its mettle once again with Glenmark Pharmaceuticals announcing the receipt of euro 25 million from German drug major Merck

Corporate hospital sector witnesses healthy growth

Corporate hospital sector witnesses healthy growth

Rediff.com   18 Dec 2006

The corporate hospital sector of the country is all set to take away a significant share of the tertiary healthcare service business from individual private healthcare providers by 2010.

Wockhardt likely to set up base in Japan

Wockhardt likely to set up base in Japan

Rediff.com   15 Dec 2006

Pharmaceutical major Wockhardt is looking at foraying into Japan either through exports or by setting up a manufacturing base.

Chinese drugs pose threat to Indian pharma

Chinese drugs pose threat to Indian pharma

Rediff.com   12 Dec 2006

Cheap bulk drug imports from China may soon post a threat to the Rs 20,000 crore (Rs 200 billion) domestic bulk drug industry.

WHO's new pact to boost Indian pharma

WHO's new pact to boost Indian pharma

Rediff.com   11 Dec 2006

The proposal will help India, one of the most cost-effective location for pharmaceutical production, to increase its growing generic exports multifold in a hassle-free regulatory environment.

Fortis eyes Trehan's Medicity

Fortis eyes Trehan's Medicity

Rediff.com   7 Dec 2006

Fortis Healthcare Limited is close to picking up a majority stake in Naresh Trehan's upcoming Medicity project in Gurgaon, with the contours of the agreement expected to be finalised within a month.

Lab norms to hit small drug firms

Lab norms to hit small drug firms

Rediff.com   6 Dec 2006

Small scale drug makers fear that they may have to shell out anything between Rs 20 lakh (Rs 2 million) to Rs 1 crore (Rs 10 million) for acquiring land and equipment as mandated by the new GLP.

Special abatement rate for drug prices on anvil

Special abatement rate for drug prices on anvil

Rediff.com   4 Dec 2006

The central government is likely to prescribe a special rate of abatement on the retail prices of drugs for calculation of excise duty.

« Prev  |